Home > > North America And Global Viral Conjunctivitis Pipeline Drugs Market- Size, Share, Growth Rate, and Forecast
The North America Viral Conjunctivitis Pipeline Drugs market was valued at $1,089.5 Million in 2023, and is projected to reach $1,302.5 Million by 2030 growing at a CAGR of 2.63% from 2024 to 2030. DST-100 segment is expected to be the highest contributor to this market, with $680.5 Million in 2023, and is anticipated to reach $776.0 by 2030, registering a CAGR of 1.94%. APD-209 segment is anticipated to reach $526.5 Million by 2030 with the highest CAGR of 3.72%. Drug Type DST-100 APD-209 BY REGION North America U.s. Canada Europe Germany U.k. France Italy Spain Rest of Europe Asia China Japan South Korea India Singapore Rest of Asia Middle East & Africa Brazil Mexico South Africa Australia Rest of MENA